Search

Your search keyword '"Plymate, Stephen R."' showing total 772 results
Start Over Author "Plymate, Stephen R."
772 results on '"Plymate, Stephen R."'

1. Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs

Author

Han, Dong, Labaf, Maryam, Zhao, Yawei, Owiredu, Jude, Zhang, Songqi, Patel, Krishna, Venkataramani, Kavita, Steinfeld, Jocelyn S., Han, Wanting, Li, Muqing, Liu, Mingyu, Wang, Zifeng, Besschetnova, Anna, Patalano, Susan, Mulhearn, Michaela J., Macoska, Jill A., Yuan, Xin, Balk, Steven P., Nelson, Peter S., Plymate, Stephen R., Gao, Shuai, Siegfried, Kellee R., Liu, Ruihua, Stangis, Mary M., Foxa, Gabrielle, Czernik, Piotr J., Williams, Bart O., Zarringhalam, Kourosh, Li, Xiaohong, and Cai, Changmeng

Subjects
Prostate cancer -- Risk factors -- Development and progression -- Care and treatment, Metastasis -- Risk factors -- Development and progression, Genetic transcription -- Analysis, Health care industry
Abstract

One critical mechanism through which prostate cancer (PCa) adapts to treatments targeting androgen receptor (AR) signaling is the emergence of ligand-binding domain-truncated and constitutively active AR splice variants, particularly AR-V7. While AR-V7 has been intensively studied, its ability to activate distinct biological functions compared with the full- length AR (AR-FL), and its role in regulating the metastatic progression of castration- resistant PCa (CRPC), remain unclear. Our study found that, under castrated conditions, AR-V7 strongly induced osteoblastic bone lesions, a response not observed with ARFL overexpression. Through combined ChIP-seq, ATAC-seq, and RNA-seq analyses, we demonstrated that AR-V7 uniquely accesses the androgen-responsive elements in compact chromatin regions, activating a distinct transcription program. This program was highly enriched for genes involved in epithelial-mesenchymal transition and metastasis. Notably, we discovered that SOX9, a critical metastasis driver gene, was a direct target and downstream effector of AR-V7. Its protein expression was dramatically upregulated in AR-V7-induced bone lesions. Moreover, we found that Ser81 phosphorylation enhanced AR-V7's pro-metastasis function by selectively altering its specific transcription program. Blocking this phosphorylation with CDK9 inhibitors impaired the AR-V7-mediated metastasis program. Overall, our study has provided molecular insights into the role of AR splice variants in driving the metastatic progression of CRPC., Introduction The androgen receptor (AR) is critical in driving prostate cancer (PCa) development, with androgen deprivation therapy (ADT) being the standard treatment for PCa patients. Although initial responses are generally [...]

Published
2024
Full Text
View/download PDF

2. Development and Validation of a New BAG-1L–Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer

Author

Neeb, Antje, Figueiredo, Ines, Gurel, Bora, Nava Rodrigues, Daniel, Rekowski, Jan, Riisnaes, Ruth, Ferreira, Ana, Miranda, Susana, Crespo, Mateus, Westaby, Daniel, de Los Dolores Fenor de La Maza, Maria, Guo, Christina, Carmichael, Juliet, Grochot, Rafael, Tunariu, Nina, Cato, Andrew C.B., Plymate, Stephen R., de Bono, Johann S., and Sharp, Adam

Published
2023
Full Text
View/download PDF

3. Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer

Author

Li, Yingming, Yang, Rendong, Henzler, Christine M, Ho, Yeung, Passow, Courtney, Auch, Benjamin, Carreira, Suzanne, Rodrigues, Daniel Nava, Bertan, Claudia, Hwang, Tae Hyun, Quigley, David A, Dang, Ha X, Morrissey, Colm, Fraser, Michael, Plymate, Stephen R, Maher, Christopher A, Feng, Felix Y, de Bono, Johann S, and Dehm, Scott M

Subjects
Urologic Diseases, Prostate Cancer, Aging, Biotechnology, Cancer, Genetics, Human Genome, Aetiology, 2.1 Biological and endogenous factors, Androgen Receptor Antagonists, Benzamides, Biomarkers, Tumor, Cell Line, Tumor, Drug Resistance, Neoplasm, Gene Rearrangement, Humans, Male, Neoplasm Metastasis, Nitriles, Phenylthiohydantoin, Prospective Studies, Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen, Whole Genome Sequencing, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeProstate cancer is the second leading cause of male cancer deaths. Castration-resistant prostate cancer (CRPC) is a lethal stage of the disease that emerges when endocrine therapies are no longer effective at suppressing activity of the androgen receptor (AR) transcription factor. The purpose of this study was to identify genomic mechanisms that contribute to the development and progression of CRPC.Experimental designWe used whole-genome and targeted DNA-sequencing approaches to identify mechanisms underlying CRPC in an aggregate cohort of 272 prostate cancer patients. We analyzed structural rearrangements at the genome-wide level and carried out a detailed structural rearrangement analysis of the AR locus. We used genome engineering to perform experimental modeling of AR gene rearrangements and long-read RNA sequencing to analyze effects on expression of AR and truncated AR variants (AR-V).ResultsAR was among the most frequently rearranged genes in CRPC tumors. AR gene rearrangements promoted expression of diverse AR-V species. AR gene rearrangements occurring in the context of AR amplification correlated with AR overexpression. Cell lines with experimentally derived AR gene rearrangements displayed high expression of tumor-specific AR-Vs and were resistant to endocrine therapies, including the AR antagonist enzalutamide.ConclusionsAR gene rearrangements are an important mechanism of resistance to endocrine therapies in CRPC.

Published
2020

4. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol.

Author

Newton, Robert U, Kenfield, Stacey A, Hart, Nicolas H, Chan, June M, Courneya, Kerry S, Catto, James, Finn, Stephen P, Greenwood, Rosemary, Hughes, Daniel C, Mucci, Lorelei, Plymate, Stephen R, Praet, Stephan FE, Guinan, Emer M, Van Blarigan, Erin L, Casey, Orla, Buzza, Mark, Gledhill, Sam, Zhang, Li, Galvão, Daniel A, Ryan, Charles J, and Saad, Fred

Subjects
Humans, Disease Progression, Phenylthiohydantoin, Androstenes, Androgen Antagonists, Receptors, Androgen, Exercise Therapy, Quality of Life, United States, Male, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Prostatic Neoplasms, Castration-Resistant, disease progression, immune function, inflammation, physical activity, tumour biology, Receptors, Androgen, Clinical Trials, Phase III as Topic, Prostatic Neoplasms, Castration-Resistant, Clinical Sciences, Public Health and Health Services, Other Medical and Health Sciences
Abstract

IntroductionPreliminary evidence supports the beneficial role of physical activity on prostate cancer outcomes. This phase III randomised controlled trial (RCT) is designed to determine if supervised high-intensity aerobic and resistance exercise increases overall survival (OS) in patients with metastatic castrate-resistant prostate cancer (mCRPC).Methods and analysisParticipants (n=866) must have histologically documented metastatic prostate cancer with evidence of progressive disease on androgen deprivation therapy (defined as mCRPC). Patients can be treatment-naïve for mCRPC or on first-line androgen receptor-targeted therapy for mCRPC (ie, abiraterone or enzalutamide) without evidence of progression at enrolment, and with no prior chemotherapy for mCRPC. Patients will receive psychosocial support and will be randomly assigned (1:1) to either supervised exercise (high-intensity aerobic and resistance training) or self-directed exercise (provision of guidelines), stratified by treatment status and site. Exercise prescriptions will be tailored to each participant's fitness and morbidities. The primary endpoint is OS. Secondary endpoints include time to disease progression, occurrence of a skeletal-related event or progression of pain, and degree of pain, opiate use, physical and emotional quality of life, and changes in metabolic biomarkers. An assessment of whether immune function, inflammation, dysregulation of insulin and energy metabolism, and androgen biomarkers are associated with OS will be performed, and whether they mediate the primary association between exercise and OS will also be investigated. This study will also establish a biobank for future biomarker discovery or validation.Ethics and disseminationValidation of exercise as medicine and its mechanisms of action will create evidence to change clinical practice. Accordingly, outcomes of this RCT will be published in international, peer-reviewed journals, and presented at national and international conferences. Ethics approval was first obtained at Edith Cowan University (ID: 13236 NEWTON), with a further 10 investigator sites since receiving ethics approval, prior to activation.Trial registration numberNCT02730338.

Published
2018

5. Supplementary Figure 7 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

6. Supplementary Figure 12 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

7. Data from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

8. Supplementary Figure 3 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

9. Supplementary Figure 2 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

10. Supplementary Table 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

11. Supplementary Figure 9 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

12. Supplementary Table 6 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

13. Supplementary Table 1 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

14. Supplementary Table 3 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

15. Supplementary Figure 8 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

16. Supplementary Materials and Methods from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

17. Supplementary Figure 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

18. Supplementary Figure 6 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

19. Supplementary Table 7 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

20. Supplementary Table 4 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

21. Supplementary Table 2 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

22. Supplementary Figure 4 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer

Author

Neeb, Antje, primary, Figueiredo, Ines, primary, Bogdan, Denisa, primary, Cato, Laura, primary, Stober, Jutta, primary, Jiménez-Vacas, Juan M., primary, Gourain, Victor, primary, Lee, Irene I., primary, Seeger, Rebecca, primary, Muhle-Goll, Claudia, primary, Gurel, Bora, primary, Welti, Jonathan, primary, Nava Rodrigues, Daniel, primary, Rekowski, Jan, primary, Qiu, Xintao, primary, Jiang, Yija, primary, Di Micco, Patrizio, primary, Mateos, Borja, primary, Bielskutė, Stasė, primary, Riisnaes, Ruth, primary, Ferreira, Ana, primary, Miranda, Susana, primary, Crespo, Mateus, primary, Buroni, Lorenzo, primary, Ning, Jian, primary, Carreira, Suzanne, primary, Bräse, Stefan, primary, Jung, Nicole, primary, Gräßle, Simone, primary, Swain, Amanda, primary, Salvatella, Xavier, primary, Plymate, Stephen R., primary, Al-Lazikani, Bissan, primary, Long, Henry W., primary, Yuan, Wei, primary, Brown, Myles, primary, Cato, Andrew C.B., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2024
Full Text
View/download PDF

23. CD38 in Advanced Prostate Cancers

Author

Robinson, Dan, Van Allen, Eliezer M., Wu, Yi-Mi, Schultz, Nikolaus, Lonigro, Robert J., Mosquera, Juan-Miguel, Montgomery, Bruce, Taplin, Mary-Ellen, Pritchard, Colin C., Attard, Gerhardt, Beltran, Himisha, Abida, Wassim, Bradley, Robert K., Vinson, Jake, Cao, Xuhong, Vats, Pankaj, Kunju, Lakshmi P., Hussain, Maha, Tomlins, Scott A., Cooney, Kathleen A., Smith, David C., Brennan, Christine, Siddiqui, Javed, Mehra, Rohit, Chen, Yu, Rathkopf, Dana E., Morris, Michael J., Solomon, Stephen B., Durack, Jeremy C., Reuter, Victor E., Gopalan, Anuradha, Gao, Jianjiong, Loda, Massimo, Lis, Rosina T., Bowden, Michaela, Balk, Stephen P., Gaviola, Glenn, Sougnez, Carrie, Gupta, Manaswi, Yu, Evan Y., Mostaghel, Elahe A., Cheng, Heather H., Mulcahy, Hyojeong, True, Lawrence D., Plymate, Stephen R., Dvinge, Heidi, Ferraldeschi, Roberta, Flohr, Penny, Miranda, Susana, Zafeiriou, Zafeiris, Tunariu, Nina, Mateo, Joaquin, Perez-Lopez, Raquel, Demichelis, Francesca, Robinson, Brian D., Schiffman, Marc, Nanus, David M., Tagawa, Scott T., Sigaras, Alexandros, Eng, Kenneth W., Elemento, Olivier, Sboner, Andrea, Heath, Elisabeth I., Scher, Howard I., Pienta, Kenneth J., Kantoff, Philip, de Bono, Johann S., Rubin, Mark A., Nelson, Peter S., Garraway, Levi A., Sawyers, Charles L., Chinnaiyan, Arul M., Guo, Christina, Crespo, Mateus, Gurel, Bora, Dolling, David, Rekowski, Jan, Sharp, Adam, Petremolo, Antonella, Sumanasuriya, Semini, Rodrigues, Daniel N., Ferreira, Ana, Pereira, Rita, Figueiredo, Ines, Mehra, Niven, Lambros, Maryou B.K., Neeb, Antje, Gil, Veronica, Seed, George, Terstappen, Leon, Alimonti, Andrea, Drake, Charles G., and Yuan, Wei

Published
2021
Full Text
View/download PDF

24. Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer.

Author

Neeb, Antje, primary, Figueiredo, Ines, additional, Bogdan, Denisa, additional, Cato, Laura, additional, Stober, Jutta, additional, Jiménez-Vacas, Juan M., additional, Gourain, Victor, additional, Lee, Irene I., additional, Seeger, Rebecca, additional, Muhle-Goll, Claudia, additional, Gurel, Bora, additional, Welti, Jonathan, additional, Nava Rodrigues, Daniel, additional, Rekowski, Jan, additional, Qiu, Xintao, additional, Jiang, Yija, additional, Di Micco, Patrizio, additional, Mateos, Borja, additional, Bielskutė, Stasė, additional, Riisnaes, Ruth, additional, Ferreira, Ana, additional, Miranda, Susana, additional, Crespo, Mateus, additional, Buroni, Lorenzo, additional, Ning, Jian, additional, Carreira, Suzanne, additional, Bräse, Stefan, additional, Jung, Nicole, additional, Gräßle, Simone, additional, Swain, Amanda, additional, Salvatella, Xavier, additional, Plymate, Stephen R., additional, Al-Lazikani, Bissan, additional, Long, Henry W., additional, Yuan, Wei, additional, Brown, Myles, additional, Cato, Andrew C.B., additional, de Bono, Johann S., additional, and Sharp, Adam, additional

Published
2024
Full Text
View/download PDF

25. The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance

Author

Wright, Jonathan L., primary, Schenk, Jeannette M., additional, Gulati, Roman, additional, Beatty, Sarah J., additional, VanDoren, Matthew, additional, Lin, Daniel W., additional, Porter, Michael P., additional, Morrissey, Colm, additional, Dash, Atreya, additional, Gore, John L., additional, Etzioni, Ruth, additional, Plymate, Stephen R., additional, and Neuhouser, Marian L., additional

Published
2024
Full Text
View/download PDF

27. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer

Author

Sharp, Adam, Welti, Jon C., Lambros, Maryou B.K., Dolling, David, Rodrigues, Daniel Nava, Pope, Lorna, Aversa, Caterina, Figueiredo, Ines, Fraser, Jennifer, Ahmad, Zai, Lu, Changxue, Rescigno, Pasquale, Kolinsky, Michael, Bertan, Claudia, Seed, George, Riisnaes, Ruth, Miranda, Susana, Crespo, Mateus, Pereira, Rita, Ferreira, Ana, Fowler, Gemma, Ebbs, Berni, Flohr, Penny, Neeb, Antje, Bianchini, Diletta, Petremolo, Antonella, Sumanasuriya, Semini, Paschalis, Alec, Mateo, Joaquin, Tunariu, Nina, Yuan, Wei, Carreira, Suzanne, Plymate, Stephen R., Luo, Jun, and de Bono, Johann S.

Published
2019
Full Text
View/download PDF

29. Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer

Author

Zadra, Giorgia, Ribeiro, Caroline F., Chetta, Paolo, Ho, Yeung, Cacciatore, Stefano, Gao, Xueliang, Syamala, Sudeepa, Bango, Clyde, Photopoulos, Cornelia, Huang, Ying, Tyekucheva, Svitlana, Bastos, Debora C., Tchaicha, Jeremy, Lawney, Brian, Uo, Takuma, D’Anello, Laura, Csibi, Alfredo, Kalekar, Radha, Larimer, Benjamin, Ellis, Leigh, Butler, Lisa M., Morrissey, Colm, McGovern, Karen, Palombella, Vito J., Kutok, Jeffery L., Mahmood, Umar, Bosari, Silvano, Adams, Julian, Peluso, Stephane, Dehm, Scott M., Plymate, Stephen R., and Loda, Massimo

Published
2019

30. Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer

Author

Zhu, Yezi, Sharp, Adam, Anderson, Courtney M., Silberstein, John L., Taylor, Maritza, Lu, Changxue, Zhao, Pei, De Marzo, Angelo M., Antonarakis, Emmanuel S., Wang, Mindy, Wu, Xingyong, Luo, Yuling, Su, Nan, Nava Rodrigues, Daniel, Figueiredo, Ines, Welti, Jonathan, Park, Emily, Ma, Xiao-Jun, Coleman, Ilsa, Morrissey, Colm, Plymate, Stephen R., Nelson, Peter S., de Bono, Johann S., and Luo, Jun

Published
2018
Full Text
View/download PDF

31. Aging

Author

Sprenger, Cynthia C., Plymate, Stephen R., Reed, May J., and Schwab, Manfred, editor

Published
2017
Full Text
View/download PDF

32. Supplementary Table S1 from Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex

Author

Nyquist, Michael D., primary, Coleman, Ilsa M., primary, Lucas, Jared M., primary, Li, Dapei, primary, Hanratty, Brian, primary, Meade, Hannah, primary, Mostaghel, Elahe A., primary, Plymate, Stephen R., primary, Corey, Eva, primary, Haffner, Michael C., primary, and Nelson, Peter S., primary

Published
2023
Full Text
View/download PDF

33. Supplemental Figures 1-4 from Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex

Author

Nyquist, Michael D., primary, Coleman, Ilsa M., primary, Lucas, Jared M., primary, Li, Dapei, primary, Hanratty, Brian, primary, Meade, Hannah, primary, Mostaghel, Elahe A., primary, Plymate, Stephen R., primary, Corey, Eva, primary, Haffner, Michael C., primary, and Nelson, Peter S., primary

Published
2023
Full Text
View/download PDF

34. Data from Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex

Author

Nyquist, Michael D., primary, Coleman, Ilsa M., primary, Lucas, Jared M., primary, Li, Dapei, primary, Hanratty, Brian, primary, Meade, Hannah, primary, Mostaghel, Elahe A., primary, Plymate, Stephen R., primary, Corey, Eva, primary, Haffner, Michael C., primary, and Nelson, Peter S., primary

Published
2023
Full Text
View/download PDF

35. Unraveling the Global Proteome and Phosphoproteome of Prostate Cancer Patient-Derived Xenografts

Author

Sychev, Zoi E, primary, Day, Abderrahman, additional, Bergom, Hannah E, additional, Larson, Gabrienne, additional, Ali, Atef, additional, Ludwig, Megan, additional, Boytim, Ella, additional, Ilsa, Coleman, additional, Corey, Eva, additional, Plymate, Stephen R, additional, Nelson, Peter S, additional, Hwang, Justin H, additional, and Drake, Justin M, additional

Published
2023
Full Text
View/download PDF

36. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer

Author

Sharp, Adam, Coleman, Ilsa, Yuan, Wei, Sprenger, Cynthia, Dolling, David, Rodrigues, Daniel Nava, Russo, Joshua W., Figueiredo, Ines, Bertan, Claudia, Seed, George, Riisnaes, Ruth, Uo, Takuma, Neeb, Antje, Welti, Jonathan, Morrissey, Colm, Carreira, Suzanne, Luo, Jun, Nelson, Peter S., Balk, Steven P., True, Lawrence D., de Bono, Johann S., and Plymate, Stephen R.

Subjects
Biology -- Usage, Cancer patients -- Health aspects, Gene expression -- Research, Prostate cancer -- Genetic aspects -- Diagnosis -- Development and progression, Health care industry
Abstract

BACKGROUND. Liquid biopsies have demonstrated that the constitutively active androgen receptor splice variant-7 (AR-V7) associates with reduced response and overall survival from endocrine therapies in castration-resistant prostate cancer (CRPC). However, these studies provide little information pertaining to AR-V7 expression in prostate cancer (PC) tissue.METHODS. Following generation and validation of a potentially novel AR-V7 antibody for IHC, AR-V7 protein expression was determined for 358 primary prostate samples and 293 metastatic biopsies. Associations with disease progression, full-length androgen receptor (AR-FL) expression, response to therapy, and gene expression were determined.RESULTS. We demonstrated that AR-V7 protein is rarely expressed (CONCLUSION. This study provides impetus to develop therapies that abrogate AR-V7 signaling to improve our understanding of AR-V7 biology and to confirm the clinical significance of AR-V7.FUNDING. Work at the University of Washington and in the Plymate and Nelson laboratories is supported by the Department of Defense Prostate Cancer Research Program (W81XWH-14-2-0183, W81XWH-12-PCRP-TIA, W81XWH-15-1-0430, and W81XWH-13-2-0070), the Pacific Northwest Prostate Cancer SPORE (P50CA97186), the Institute for Prostate Cancer Research, the Veterans Affairs Research Program, the NIH/National Cancer Institute (P01CA163227), and the Prostate Cancer Foundation. Work in the de Bono laboratory was supported by funding from the Movember Foundation/Prostate Cancer UK (CEO13-2-002), the US Department of Defense (W81XWH-13-2-0093), the Prostate Cancer Foundation (20131017 and 20131017-1), Stand Up To Cancer (SU2C-AACR-DT0712), Cancer Research UK (CRM108X-A25144), and the UK Department of Health through an Experimental Cancer Medicine Centre grant (ECMC-CRM064X)., IntroductionProstate cancer (PC) is the most commonly diagnosed noncutaneous cancer and the second leading cause of male cancer-related death in the Western world (1). Androgen receptor (AR) signaling is critical [...]

Published
2019
Full Text
View/download PDF

38. A Compound that Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer

Author

Uo, Takuma, primary, Ojo, Kayode K., additional, Sprenger, Cynthia C., additional, Epilepsia, Kathryn Soriano, additional, Perera, B. Gayani K., additional, Damodarasamy, Mamatha, additional, Sun, Shihua, additional, Kim, Soojin, additional, Hogan, Hannah H., additional, Hulverson, Matthew A., additional, Choi, Ryan, additional, Whitman, Grant R., additional, Barrett, Lynn K., additional, Michaels, Samantha A., additional, Xu, Linda H., additional, Pang, Haley J., additional, Nguyen, Matthew M., additional, Vigil, Anna-Lena B.G., additional, Kamat, Varun, additional, Sullivan, Lucas B., additional, Sweet, Ian R., additional, Vidadala, Ram, additional, Maly, Dustin J., additional, Van Voorhis, Wesley C., additional, and Plymate, Stephen R., additional

Published
2023
Full Text
View/download PDF

40. Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth

Author

Nyquist, Michael D., Ang, Lisa S., Corella, Alexandra, Coleman, Ilsa M., Meers, Michael P., Christiani, Anthony J., Pierce, Cordell, Janssens, Derek H., Meade, Hannah E., Bose, Arnab, Brady, Lauren, Howard, Timothy, De Sarkar, Navonil, Frank, Sander B., Dumpit, Ruth F., Dalton, James T., Corey, Eva, Plymate, Stephen R., Haffner, Michael C., Mostaghel, Elahe A., and Nelson, Peter S.

Subjects
Prostate cancer -- Development and progression -- Drug therapy, Androgens -- Physiological aspects -- Usage, Health care industry
Abstract

Prostate cancer (PC) is driven by androgen receptor (AR) activity, a master regulator of prostate development and homeostasis. Frontline therapies for metastatic PC deprive the AR of the activating ligands testosterone (T) and dihydrotestosterone (DHT) by limiting their biosynthesis or blocking AR binding. Notably, AR signaling is dichotomous, inducing growth at lower activity levels, while suppressing growth at higher levels. Recent clinical studies have exploited this effect by administration of supraphysiological concentrations of T, resulting in clinical responses and improvements in quality of life. However, the use of T as a therapeutic agent in oncology is limited by poor drug-like properties as well as rapid and variable metabolism. Here, we investigated the antitumor effects of selective AR modulators (SARMs), which are small-molecule nonsteroidal AR agonists developed to treat muscle wasting and cachexia. Several orally administered SARMs activated the AR program in PC models. AR cistromes regulated by steroidal androgens and SARMs were superimposable. Coregulatory proteins including HOXB13 and GRHL2 comprised AR complexes assembled by both androgens and SARMs. At bioavailable concentrations, SARMs repressed MYC oncoprotein expression and inhibited the growth of castration-sensitive and castration-resistant PC in vitro and in vivo. These results support further clinical investigation of SARMs for treating advanced PC., Introduction Prostate secretory epithelial cells and neoplastic derivatives are dependent on the androgen receptor (AR) to regulate differentiation, metabolism, growth, and survival (1-3). Currently, inhibition of AR signaling using androgen [...]

Published
2021
Full Text
View/download PDF

41. Supplemental Tables 1 and 2 from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

42. Supplemental Figure 3 from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

43. Data from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Methods, Tables and Figures from Antitumor Activity of the IGF-1/IGF-2–Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models

Author

Weyer-Czernilofsky, Ulrike, primary, Hofmann, Marco H., primary, Friedbichler, Katrin, primary, Baumgartinger, Rosa, primary, Adam, Paul J., primary, Solca, Flavio, primary, Kraut, Norbert, primary, Nguyen, Holly M., primary, Corey, Eva, primary, Liu, Gang, primary, Sprenger, Cynthia C., primary, Plymate, Stephen R., primary, and Bogenrieder, Thomas, primary

Published
2023
Full Text
View/download PDF

45. Supplemental Figure 1 from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

46. Supplemental Information from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 2 from VEGF/Neuropilin-2 Regulation of Bmi-1 and Consequent Repression of IGF-IR Define a Novel Mechanism of Aggressive Prostate Cancer

Author

Goel, Hira Lal, primary, Chang, Cheng, primary, Pursell, Bryan, primary, Leav, Irwin, primary, Lyle, Stephen, primary, Xi, Hualin Simon, primary, Hsieh, Chung-Cheng, primary, Adisetiyo, Helty, primary, Roy-Burman, Pradip, primary, Coleman, Ilsa M., primary, Nelson, Peter S., primary, Vessella, Robert L., primary, Davis, Roger J., primary, Plymate, Stephen R., primary, and Mercurio, Arthur M., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Figure 3 from VEGF/Neuropilin-2 Regulation of Bmi-1 and Consequent Repression of IGF-IR Define a Novel Mechanism of Aggressive Prostate Cancer

Author

Goel, Hira Lal, primary, Chang, Cheng, primary, Pursell, Bryan, primary, Leav, Irwin, primary, Lyle, Stephen, primary, Xi, Hualin Simon, primary, Hsieh, Chung-Cheng, primary, Adisetiyo, Helty, primary, Roy-Burman, Pradip, primary, Coleman, Ilsa M., primary, Nelson, Peter S., primary, Vessella, Robert L., primary, Davis, Roger J., primary, Plymate, Stephen R., primary, and Mercurio, Arthur M., primary

Published
2023
Full Text
View/download PDF

49. Supplemental Figure Legends from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

50. Supplemental Figure 2 from BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer

Author

Asangani, Irfan A., primary, Wilder-Romans, Kari, primary, Dommeti, Vijaya L., primary, Krishnamurthy, Pranathi M., primary, Apel, Ingrid J., primary, Escara-Wilke, June, primary, Plymate, Stephen R., primary, Navone, Nora M., primary, Wang, Shaomeng, primary, Feng, Felix Y., primary, and Chinnaiyan, Arul M., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results